Cited by

• The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.

  Honess DJ, Donaldson J, Workman P, Bleehen NM. Honess DJ, et al. Br J Cancer. 1985 Jan;51(1):77-84. doi: 10.1038/bjc.1985.11. Br J Cancer. 1985. PMID: 3966973 Free PMC article.
• Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.

  Ehrsson H, Eksborg S, Osterborg A, Mellstedt H, Lindfors A. Ehrsson H, et al. Med Oncol Tumor Pharmacother. 1989;6(2):151-4. doi: 10.1007/BF02985238. Med Oncol Tumor Pharmacother. 1989. PMID: 2747308
• Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat.

  Ahmed AE, Hsu TF, el-Azhary RA, Moawad H, Farrish HH Jr, Costanzi J. Ahmed AE, et al. Cancer Chemother Pharmacol. 1982;8(3):271-6. doi: 10.1007/BF00254049. Cancer Chemother Pharmacol. 1982. PMID: 7127659
• The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

  Hinchliffe M, McNally NJ, Stratford MR. Hinchliffe M, et al. Br J Cancer. 1983 Sep;48(3):375-83. doi: 10.1038/bjc.1983.202. Br J Cancer. 1983. PMID: 6615699 Free PMC article.
• Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

  Yagi MJ, Bekesi JG, Daniel MD, Holland JF, De Barbieri A. Yagi MJ, et al. Cancer Chemother Pharmacol. 1984;12(2):70-6. doi: 10.1007/BF00254592. Cancer Chemother Pharmacol. 1984. PMID: 6421500